I am long but wanted to see how many shares were available to short
I cant get shares to short from the Computer at Ameritrade and when I call them and say I have shares to deliver and want to short them they want the Cusip numbers before they will enter an order
How can others do this and get stock to short
It is killing the company and people who have to play by the book
Dance caught me by surprise. You can also see how Adam F is lining up on their side and against Mankind.
Expect a big Flash article as to how great this product will be and how they will be market leaders.
Had not thought of this SHORT BEAR ATTACK.
We will deal for this now while they decide to go on their road show. The good part is when they have the Red Herring printed and start their road show they will validate and super-size the market for inhaled insulin and they will also talk about all the benefits of inhaled insulin
They will also qualify the lack of any morbidity or mortality including lung cancer
Just think of the benefits to MNKD. Cant wait to see how AF trys to spin this one
I think it is great that we are finally in Control
Does anyone know when the higest round of money has been raised in the past 3 years
We must look for another round if it get to the 10 -15% above that higest point
It is all good and like Matese said stay long
YOu just may want not to be scared because it will drop but If it is higher than past rounds you may find it as a very short term buying opportunity that will bounce back to the offering price
This is running up very fast and he would be stupid not to take advantage of the price
The Key point is that can he take advantage of a price move that shows a higher price to raise money than what has been done in the past
Could you ever get a loan when you had no money?
An old Company Chairman taught me something very important and that is you never Raise Cash when you need it !!!! That is why I expect the cash raise to come very soon and not let the bank balance run dry. This will ensure the survival of the company through any issue that may come up over the next months and through the 1st Q of Sales
I would not be surprised if it is not for 100M very close to this reporting period and Conference Call.
Al may fund it as a bridge Loan or they may do it via an offering at a valuation much higher than what has come in the past rounds.
People should be very aware of this and recognize it will be a buying opportunity.
Longs should start talking about this potential so that it does not catch anyone on the blind side
I agree with you all the way from Sunny Isles. In order to make some money with this situation one may want to keep say 10 -15 % of their value of MNKD to create a trading position around the shorts.
The shorts will continue to allow the stock to slowly rise and then when you least expect it . BANG ...Short Bear attack and the week hands will be flushed out and the shorts will cover with a 10% profit . We now know that we are moving forward toward approval .
There may be labeling issues extended compliance issues to monitor but approval is on the way.
The shorts need to break even they will take every opportunity to do it. There will be opportunity for them . I do see one big opportunity that everybody needs to be aware of and that is an additional raise of capital to make sure the company has enough money to get through the end of the year. However I think with approval on the way it may be an up round and not as diluted as many think
In reality there is not a higher incidence of cancer from the General population. However if you reread the ADCOM hearing there was considerable concern that was registered by bot the FDA and one physician casting a no vote on Type 1 due to the potential
The chairman and 3 others made comments to consider that they have some worry that there may be a potential of a problem because there is such a long term use of the drug and never before has (except for Exubera) has there been a drug administered via the lungs to treat a disease that was not involving the lungs or respiratory system.
There also were a couple of unexplained lung tumors or cancers from Exubera
All the doctors on the Panel felt this was such a good therapy with great potential that it was warented to vote yes with the notion that the FDA would work with the company to create post market survailence and monitor this issue
This is one of the programs that need to be put into place with the company doing the heavy lifting on their end. It takes time to put this together and that is why we have the extension .
Not new to this at all was a senior vp at a BP . But always on the other side waiting for the FDA . I also like to encourage discussion
You must admit this has been a long haul and is still not over .
I anticipate a significant amount of PM follow up and label restrictions but it is a huge market opportunity with a great product
I also recognize that there is a small potential of another rejection but very doubtful
Lots of opportunity in the next weeks if you have a clear plan and understanding of what can happen
Your insight is great.
This is great information brought right in front of everyone to see
Any thoughts of price points
How low will it go before using that dry powder
No bashing I am curious would like to be ahead of it and think of buying points
I am into this whole heartedly and financially
I just wonder in the past how many days prior to a PDUFA has the FDA mandated an extension
If it is two weeks we are getting close to D day . It is getting exciting
If they exersise a delay any thoughts when it may happen
Any data as to previous delays that have been excersied and when?
Any historical data whether approval has been denied after a delay
When they must inform a company that the hearing for approval will be delayed
I think this may be the next indicator of success
You must re visit the ADCOM meeting to understand that the FDA said several times that we have been working on the labeling issues with the sponsor. They said this at least 3 times during questions made after there presentation. The other issues that showed that they were being conservative in doing their statistical analysis of A1c success and its effectiveness.
The statistiscian could have pushed back very hard if she felt that there was no benefit to the drug SHE DID NOT iin the end she said the statistical values although at the borders of acceptable were a pass because of the equivalency and safety of the drug..
The FDA also would never say that the label was being worked on if there was major issues with the potential for approval
Best of luck
The note or column was a marketing piece for his blog . It was fairly written to expand his user base why get so many people upset so they won't tune in